Lu J., Lonergan P.E., Nacusi L.P., Wang L., Schmidt L.J., Sun Z., Van der Steen T., Boorjian S.A., Kosari F., Vasmatzis G., Klee G.G., Balk S.P., Huang H., Wang C., Tindall D.J.
Journal of Urology 2014
Purpose: Spliced variant forms of androgen receptor were recently identified in castration resistant prostate cancer cell lines and clinical samples. We identified the cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cell lines and determined the clinical significance of androgen receptor splice variant regulated genes. Materials and Methods: The castration resistant prostate cancer cell line 22Rv1, which expresses full-length androgen receptor and androgen receptor splice variants endogenously, was used as the research model. We established 22Rv1-ARFL-/ARV+ and 22Rv1-ARFL-/ARV- through RNA interference. Chromatin immunoprecipitation coupled with next generation sequencing and microarray techniques were used to identify the cistrome and gene expression profiles of androgen receptor splice variants in the absence of androgen. Results: Androgen receptor splice variant binding sites were identified in 22Rv1-ARFL-/ARV+…(vermás)